Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amunix Operating, a biotechnology company developing polypeptides which can be recombinantly fused or chemically conjugated to other peptides, proteins and small molecules, has entered into a Services and Supply Agreement with the University of Nebraska-Lincoln Biological Process Development Facility to provide kilogram-scale, GMP-Grade XTEN for chemical conjugation.
Subscribe to our email newsletter
XTEN is Amunix’s proprietary protein-based polymer that mimics the biophysical properties of PEG and is used to extend the half-life of genetically fused therapeutic proteins and peptides.
"We are pleased to announce this agreement with the University of Nebraska-Lincoln. It enables us to offer a service to our partners and customers that provides a seamless supply of XTEN from preclinical quantities to the larger GMP-grade quantities necessary for use in clinical trials," said Volker Schellenberger, PhD, Amunix President and CEO.
"Amunix is now positioned to provide the enabling technology support for our partners and customers as they move candidate drugs through development towards commercialization."
XTEN is a proprietary recombinant polypeptide that extends the in vivo half-life of therapeutics payloads. XTEN consists of naturally occurring hydrophilic amino acids and is biodegradable.
Pharmaceuticals such as proteins, peptides and synthetic compounds can be XTENylated via chemical conjugation or genetic fusion. The XTEN platform technology is unique in that it offers better safety options than other half-life extension technologies for developing new therapeutics and minimizes immunogenicity risks due to its solubility and high hydrophilic properties.
Amunix has formed significant partnerships with Biogen Idec, Janssen Biotech, Inc., Versartis, Inc., and other leading organizations to develop products in a wide range of therapeutic areas. Amunix is actively seeking new partnerships to pursue additional therapeutic applications for its polymer.